Send Inquiry

Request To Call Back

MYDEKLA DACLATASVIR TABLETS

Get a Price/Quote

MOQ : 1 Bottle

MYDEKLA DACLATASVIR TABLETS Specification

Indication
Chronic Hepatitis C Virus (HCV) infection

Pacakaging (Quantity Per Box)
28 tablets per blister pack

Salt Composition
Daclatasvir Dihydrochloride 60mg

Origin of Medicine
India

Dosage Form
Oral tablet

Drug Type
Prescription Only Medicine

Ingredients
Daclatasvir Dihydrochloride

Physical Form
Tablets

Function
Antiviral agent, inhibits HCV replication

Recommended For
Treatment of chronic Hepatitis C infection in adults

Dosage
As directed by the physician

Dosage Guidelines
Take orally, do not crush or chew; follow physicians instructions

Suitable For
Adults

Quantity
28 Tablets

Storage Instructions
Store below 30C, protect from moisture and light

Color
Light yellow

Contraindications
Hypersensitivity to Daclatasvir or any inactive ingredients

Therapeutic Class
Direct-acting antiviral (DAA)

Side Effects
Fatigue, headache, nausea, diarrhea

Shape
Oval, film-coated

Warning
Not recommended for use in children or during pregnancy unless specifically prescribed

Brand Name
MYDEKLA

Administration Route
Oral

Shelf Life
24 months

Prescription Required
Yes

Interactions
Potential interaction with other antiviral medications and certain CYP3A inducers/inhibitors

MYDEKLA DACLATASVIR TABLETS Trade Information

Minimum Order Quantity
1 Bottle

Packaging Details
PACK OF 28 TABLETS

Main Domestic Market
All India

About MYDEKLA DACLATASVIR TABLETS

PRODUCT DETAILS

BRAND NAME: MYDEKLA

CONTENT: DACLATASVIR

STRENGTH: 60MG

PACKAGING: PACK OF 28 TABLETS

MANUFACTURED BY: MYLAN

Note : -MYDEKLA Is A Prescription Drug And Should Be UsedUnder Proper Medical Guidance And Advice. Do Not Share The Medicine WithOthers, Since They May Be Suffering From A Problem That Is Not EffectivelyTreated By This Drug.............

Effective Treatment for Chronic Hepatitis C

MYDEKLA Daclatasvir Tablets offer targeted antiviral therapy for adults diagnosed with chronic HCV infection. By inhibiting virus replication, this medication helps reduce viral load and supports liver health. Prescribed by healthcare professionals, MYDEKLA forms part of a comprehensive Hepatitis C treatment plan.

Safety and Administration Guidelines

MYDEKLA must be taken orally as directed by your physician. Patients should swallow the tablets whole without crushing or chewing. The product is not recommended for children or pregnant individuals unless specifically prescribed. Consultation with a healthcare provider is essential to ensure safe and effective use, particularly if other medications are being taken.

Convenient Packaging and Storage

Each box of MYDEKLA contains 28 tablets in a protective blister pack, ensuring quality and ease of dosing. For optimal preservation, store tablets below 30C and safeguard them from moisture and light. Always check the expiration date and retain medications in their original packaging until use.

FAQs of MYDEKLA DACLATASVIR TABLETS:

Q: How should I take MYDEKLA Daclatasvir Tablets for Hepatitis C treatment?

A: MYDEKLA tablets should be taken orally exactly as directed by your physician. Swallow the film-coated tablets whole with water, without crushing or chewing. Daily dosage and duration depend on your doctors instructions.

Q: What are the main benefits of using MYDEKLA for chronic Hepatitis C infection?

A: MYDEKLA inhibits replication of the Hepatitis C Virus, reducing viral loads in adults diagnosed with chronic HCV infection. When taken as directed, it can significantly aid in virus suppression as part of a comprehensive antiviral regimen.

Q: When should MYDEKLA not be used?

A: MYDEKLA is contraindicated in patients who have hypersensitivity or allergic reactions to Daclatasvir or any inactive ingredients in the tablet. It should also be avoided unless specifically prescribed for children or use during pregnancy.

Q: Are there any potential drug interactions with MYDEKLA?

A: Yes, MYDEKLA may interact with certain other antiviral medications, CYP3A inducers, or inhibitors. Inform your healthcare provider about all medicines and supplements you are taking to prevent adverse interactions.

Q: What side effects might occur while taking MYDEKLA Daclatasvir Tablets?

A: Common side effects include fatigue, headache, nausea, and diarrhea. If you experience severe or persistent symptoms, contact your healthcare professional for advice.

Q: Where is MYDEKLA manufactured and who can supply it?

A: MYDEKLA is manufactured in India and is available through authorized distributors, exporters, suppliers, traders, and wholesalers. Ensure you purchase from reputable sources with a valid prescription.

Q: What is the recommended process for storing MYDEKLA Tablets?

A: Store MYDEKLA below 30C, away from moisture and light, in its original blister pack. Always check the expiry date and avoid storing tablets in humid environments to maintain efficacy.

Tell us about your requirement